Genscript Biotech Announces CEO Resignation and Leadership Changes
Genscript Biotech (HK:1548) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Genscript Biotech Corporation has announced the resignation of Dr. Liu Zhenyu from his role as rotating chief executive officer, effective 31 December 2024, as he pursues personal career development. Dr. Li Zhu, the current Executive Director and chief strategy officer, will take over as chairman of Probio Technology Limited, a subsidiary of Genscript. The company expressed gratitude for Dr. Liu’s contributions, ensuring a smooth transition for its leadership and maintaining stability in its operations.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.